Suanfarma Suanfarma

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"DelSiTech","sponsor":"DelSiTech","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"DelSiTech","sponsor":"IVERIC bio","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$1.2 million","newsHeadline":"Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura\u00ae","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"FINLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical"},{"orgOrder":0,"company":"DelSiTech","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Preclinical","country":"FINLAND","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Preclinical"},{"orgOrder":0,"company":"DelSiTech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DelSiTech Announces Positive Topline Clinical Data from Phase 1 Trial with its Sustained Release Eye Drop Platform","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase I","country":"FINLAND","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase I"},{"orgOrder":0,"company":"DelSiTech","sponsor":"DRW Venture Capital LLC","pharmaFlowCategory":"D","amount":"$10.8 million","upfrontCash":"Undisclosed","newsHeadline":"DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Undisclosed","country":"FINLAND","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by DelSiTech

    Menu

    DelSiTech

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              DelSiTech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DelSiTech Announces Closing of EUR 10 Million Financing Round to Advance its Silica-Based Drug Delivery Technology Platform

              Details:

              The proceeds will be used to advance its unique, in-house, silica-based, drug delivery technology platform into clinical development, including DST1308 in Chronic Hepatitis B, as well as expanding its in-house manufacturing capability.

              Lead Product(s): Entecavir

              Therapeutic Area: Infections and Infectious Diseases Product Name: DST1308

              Highest Development Status: Undisclosed Product Type: Small molecule

              Partner/Sponsor/Collaborator: DRW Venture Capital LLC

              Deal Size: $10.8 million Upfront Cash: Undisclosed

              Deal Type: Financing January 16, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DelSiTech

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DelSiTech Announces Positive Topline Clinical Data from Phase 1 Trial with its Sustained Release Eye Drop Platform

              Details:

              DST-2105 is based on DelSiTech's Silica Matrix formulation technology which enables the once daily administration of eye drops in the cul-de-sac of the eye, which is investigated for relieving dry eye symptoms.

              Lead Product(s): DST-2105

              Therapeutic Area: Ophthalmology Product Name: DST-2105

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DelSiTech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DelSiTech Awarded a Grant to Develop Controlled and Sustained Release Injectables for Prophylactic HIV Vaccine

              Details:

              DelSiTech will develop long-acting injectable formulations ensuring slow release of HIV vaccine. Silica Matrix technology provides controlled long-acting drug release w/o interfering with its therapeutic functions and is compatible with small molecules and large biologics.

              Lead Product(s): Undisclosed

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Vaccine

              Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding March 15, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DelSiTech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Iveric Bio and DelSiTech Enter Exclusive Agreement for Development of Sustained Release Zimura®

              Details:

              As part of Iveric Bio’s lifecycle expansion plan for Zimura (avacincaptad pegol), the Company is committed to developing sustained release technologies for the treatment of age-related macular degeneration (AMD).

              Lead Product(s): Avacincaptad Pegol

              Therapeutic Area: Ophthalmology Product Name: Zimura

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: IVERIC bio

              Deal Size: Undisclosed Upfront Cash: $1.2 million

              Deal Type: Agreement July 05, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              DelSiTech

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Finland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DelSiTech Enters into an Exclusive Licensing Agreement with Optifye Therapeutics for the Development of a Controlled Release Ophthalmic Eye Drop Product

              Details:

              Controlled release of dexamethasone eye drops, based on DelSiTech™ Silica Matrix technology, is a revolutionary eye drop product that is applied as a single drop, once daily under the eye lid which maintains therapeutic drug concentration in the eye.

              Lead Product(s): Dexamethasone

              Therapeutic Area: Ophthalmology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Optifye Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement March 28, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Inke S.A: APIs manufacturing plant.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY